

**Supplementary Table S1: Summary of adapted international guidelines**

AASLD 2018		
ALT ULN: 25 IU/mL	F2: NSP F2 used: 7kPa	F4: NSP F4 used: 11kPa
<ul style="list-style-type: none"> <li>• If Ag HBe positive: <ul style="list-style-type: none"> <li>◦ ALT &gt; 2 x ULN &amp; HBV DNA <math>\geq 4.3 \log 10/\text{mL}</math></li> <li>◦ ALT = 1-2 ULN &amp; HBV DNA <math>\geq 4.3 \log 10/\text{mL}</math> &amp; fibrosis <math>\geq \text{F2}</math></li> </ul> </li> <li>• If AgHBe negative: <ul style="list-style-type: none"> <li>◦ ALT &gt; 2 x ULN &amp; HBV DNA <math>\geq 3.3 \log 10/\text{mL}</math></li> <li>◦ ALT = 1-2 ULN &amp; HBV DNA <math>\geq 3.3 \log 10/\text{mL}</math> &amp; fibrosis <math>\geq \text{F2}</math></li> </ul> </li> <li>• Compensated F4 &amp; HBV DNA <math>\leq 3.3 \log 10/\text{mL}</math></li> <li>• Decompensated F4</li> </ul>		
APASL 2015		
ALT ULN : 40 IU/mL	F2: 8kPa	F4: 11kPa
<ul style="list-style-type: none"> <li>• Compensated cirrhosis &amp; HBV DNA &gt; <math>3.3 \log 10/\text{mL}</math></li> <li>• Decompensated cirrhosis &amp; detectable HBV DNA</li> <li>• If AgHBe positive : <ul style="list-style-type: none"> <li>◦ &amp; HBV DNA &gt; <math>4.3 \log 10/\text{mL}</math> &amp; ALT &gt; 2 x ULN (1 month)</li> <li>◦ &amp; HBV DNA &gt; <math>4.3 \log 10/\text{mL}</math> &amp; LSM <math>\geq \text{F2}</math></li> </ul> </li> <li>• ALT &gt; ULN &amp; LSM <math>\geq \text{F2}</math></li> <li>• If AgHBe negative <ul style="list-style-type: none"> <li>◦ &amp; HBV DNA &gt; <math>3.3 \log 10/\text{mL}</math> &amp; ALT &gt; 2 x ULN (1 month)</li> <li>◦ &amp; HBV DNA &gt; <math>3.3 \log 10/\text{mL}</math> &amp; LSM <math>\geq \text{F2}</math></li> </ul> </li> <li>• Age &gt; 35 years &amp; LSM <math>\geq \text{F2}</math></li> </ul>		
EASL 2017		
ALT ULN : 40 IU/mL	F2: 6 kPa	F4: 12 kPa if ALT = ]ULN-5xULN[ or 9kPa if ALT $\leq$ ULN
<ul style="list-style-type: none"> <li>• Compensated or decompensated cirrhosis &amp; detectable HBV DNA</li> <li>• HBV DNA &gt; <math>4.3 \log 10/\text{mL}</math> &amp; ALT &gt; 2 x ULN</li> <li>• HBV DNA &gt; <math>3.3 \log 10/\text{mL}</math> &amp; moderate liver necro-inflammation or fibrosis</li> <li>• AgHBe positive &amp; high level of HBV DNA* &amp; age &gt; 30 years</li> </ul>		

ALT: Alanine Aminotransferase; AASLD: American Association for the Study of Liver Disease; APASL: Asian Pacific Association for the Study of the Liver; ASL: European Association for the Study of the Liver; F2 : significant liver fibrosis, F4 : cirrhosis, NSP : Non Specified in the guidelines ; ULN : Upper Limit of Normal, \* HBV DNA non specified in the guidelines, decision to use 20,000 as the threshold

**Supplementary Table S2. Performance of simplified algorithms to select women eligible for long-term antiviral treatment 6 months after delivery among women ineligible for TDF prophylaxis (n = 362)**

	TREAT-B			Ta - Prohm	WHO
Cut-off	$\geq 2$	$\geq 3$	4	NA	NA
AASLD 2018					
AUROC	0.79 (0.75-0.83)			0.75 (0.70-0.79)	0.68 (0.63-0.73)
TP	14	2	/	14	14
FP	48	9	/	48	94
TN	292	331	/	292	246
FN	8	20	/	8	8
Sen	63.6	9.1	NA	63.6	63.6
Spe	85.9	97.4	NA	85.9	72.4
EASL 2015					
AUROC	0.54 (0.48-0.59)			0.51 (0.46-0.56)	0.62 (0.57-0.67)
TP	4	2	/	4	11
FP	58	9	/	58	97
TN	283	332	/	283	244
FN	17	19	/	17	10
Sen	19.1	9.5	NA	19.1	52.4
Spe	83.0	97.4	NA	83.0	71.6

Abbreviations: AASLD : American Association for the Study of Liver Disease; AUROC : Area Under the Receiver Operating Characteristic; EASL : European Association for the Study of the Liver; FN : False Negative; FP : False Positive; Sen : Sensitivity; Spe : Specificity; TN : True Negative, TP : True Positive